Angiotensin II in Liver Transplantation

Description

The purpose of this study is to determine the efficacy and safety of Angiotensin II as a second-line vasopressor (drug that raises the blood pressure) during liver transplantation.

Conditions

Liver Transplant; Complications, Vasoplegia

Talk to us

Study Overview

On this page

Study Details

Study overview

The purpose of this study is to determine the efficacy and safety of Angiotensin II as a second-line vasopressor (drug that raises the blood pressure) during liver transplantation.

Angiotensin II in Liver Transplantation (AngLT-1): A Pilot Randomized Controlled Trial

Angiotensin II in Liver Transplantation

Condition
Liver Transplant; Complications
Intervention / Treatment

-

Contacts and Locations

San Francisco

University of California, San Francisco, San Francisco, California, United States, 94143

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Age \> or = 18 years
  • * Liver transplantation from a deceased donor
  • * Model for End-stage Liver Disease Sodium (MELD-Na) score \> or = 25 at the time of transplant (not counting MELD exception points)
  • * Patient requiring \> 0.05 mcg/kg/min of norepinephrine (NE) during LT
  • * Living-donor liver transplantation (LDLT)
  • * Split liver transplantation (isolated right or left lobe)
  • * Donation after cardiac death (DCD) without normothermic machine perfusion (NMP)
  • * Acute liver failure (ALF)
  • * Listed for or receiving simultaneous liver-kidney transplantation (SLKT)
  • * Liver re-transplantation (patient who has previously received a liver transplant)
  • * Preoperative treatment with angiotensin II receptor blocker or angiotensin converting enzyme inhibitor (within 48 h)
  • * Portopulmonary hypertension
  • * Left ventricular systolic dysfunction (defined as ejection fraction \< 45%)
  • * Active bronchospasm at time of LT
  • * History of thrombotic or embolic disease, inherited hypercoagulable disorder, or therapeutic anticoagulation
  • * Portal vein thrombosis
  • * Celiac stenosis
  • * End-stage renal disease (chronic eGFR \< 15 mL/min/1.73 m2 or chronic RRT - not including AKI requiring RRT)
  • * History of Raynaud's disease
  • * Known history of allergy to synthetic human angiotensin II
  • * Subject intubated and/or mechanically ventilated prior to entering OR for LT
  • * Presence of other condition or abnormality that would compromise the safety of the patient or quality of the data

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of California, San Francisco,

Michael P Bokoch, M.D., Ph.D., PRINCIPAL_INVESTIGATOR, Department of Anesthesia and Perioperative Care, University of California, San Francisco

Study Record Dates

2026-09-01